COPD And Quitting Smoking

New research shows that patients with chronic obstructive pulmonary disease (COPD) have higher smoking cessation rates with varenicline compared with placebo.



In a multinational study involving 27 centers, researchers from UCLA followed 504 patients with mild to moderate COPD who were randomized to receive either varenicline (N=250) or placebo (N=254). At weeks 9-12, abstinence rates for patients treated with varenicline were higher than for the placebo group (42.3 percent vs 8.8 percent), and they remained higher through 52 weeks (18.6 percent vs 5.6 percent).



Nausea, abnormal dreams, upper respiratory tract infection, and insomnia were the most commonly reported events with varenicline; however, serious adverse events were infrequent in both treatment groups.



Researchers conclude that varenicline was more effective than placebo for smoking cessation in patients with mild to moderate COPD.



This article is published in the March issue of Chest, the peer-reviewed journal of the American College of Chest Physicians: Chest 2011; 139(3):591-599.